Eli Lil­ly scraps a tau pro­gram for Alzheimer’s, echo­ing past fail­ures and cast­ing doubt on en­tire ap­proach

Dur­ing Tues­day’s third quar­ter earn­ings call with in­vestors, Eli Lil­ly re­vealed it sub­mit­ted its Alzheimer’s can­di­date do­nanemab for ap­proval, us­ing the same ac­cel­er­at­ed path­way chart­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER